Manufacturing Shift Lead
Alexion
Manufacturing Shift Lead
Alexion
Global biopharmaceuticals focusing on rare diseases
Location: Athlone, Ireland
Shift pattern: 24/7 shift rotation
At Alexion, we develop and manufacture medicines for people living with rare and ultra-rare diseases. At our new Bulk Drug Substance facility in Athlone, we are building a manufacturing culture where safety, quality and operational excellence come first.
We are looking for an experienced Manufacturing Shift Lead to lead a team of Bioprocess Technicians and oversee manufacturing activities across our 24/7 operation.
This is a hands-on leadership role where you will help ensure that production activities are completed safely, efficiently and in accordance with approved procedures, batch records and current Good Manufacturing Practice requirements.
You will bring:
This is an opportunity to help shape the culture and performance of a new manufacturing facility while leading work that directly supports the supply of medicines to patients with rare diseases.
You will work in a technically challenging environment, collaborate with experienced colleagues across multiple functions and play an important role in developing the capabilities of the wider manufacturing team.
Apply now to help us build a safe, high-performing and patient-focused manufacturing operation in Athlone.
Date Posted
02-Nov-2026Closing Date
16-Nov-2026Our mission is to build an inclusive and equitable environment. We want people to feel they belong at AstraZeneca and Alexion, starting with our recruitment process. We welcome and consider applications from all qualified candidates, regardless of characteristics. We offer reasonable adjustments/accommodations to help all candidates to perform at their best. If you have a need for any adjustments/accommodations, please complete the section in the application form.Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.
Explore more opportunities at Alexion